title: Results in treatment of early breast cancers and the level of selected metalloproteinases.
abstract: BACKGROUND
  Breast cancer is the most common malignancy in women in the U.S. and Europe. In the early stages of the disease, women are treated surgically, which is supplemented with hormonal therapy, immuno-, chemo- or radiotherapy. Postoperative qualification for further treatment is based on clinical stage, the pathology of the tumor and classic prognostic factors. Despite that, among patients with breast cancer in early stages of clinical advancement, there is a relatively large proportion of observed tumor recurrence. These observations oblige the search for additional prognostic factors that determine the progression of the disease faster, according to which, could emerge a group of women at increased risk of recurrence of the disease.
  
  
  OBJECTIVE
  The aim of this paper is to determine the meaning of the expression of selected metalloproteinases as prognostic factors in breast cancer.
  
  
  METHODS
  The study group consisted of 108 patients ages 26 to 86 years treated surgically from 1994 to 2000 because of primary breast cancer in the early clinical stage, ie stage I and II according to TNM classification.
  
  
  RESULTS
  Between two of the tested metalloproteinases (MMP-2 and MMP-11) only MMP-2 appears to have prognostic significance in early forms of breast cancer, and its strong expression is associated with shorter survival.
authors.affiliation: Department of Obstetrics and Gynecology, Jagiellonian University Medical College, Kraków, Poland.
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Wadowska-Jaszczyńska
authors.forename: Robert
authors.initials: R
authors.lastname: Jach
authors.forename: Klaudia
authors.initials: K
authors.lastname: Stangel-Wócikiewicz
authors.forename: Monika
authors.initials: M
authors.lastname: Kabzińska-Turek
authors.forename: Paulina
authors.initials: P
authors.lastname: Przybylska
authors.forename: Antoni
authors.initials: A
authors.lastname: Basta
authors.forename: Hubert
authors.initials: H
authors.lastname: Huras
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Dyduch
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Radoń-Pokracka
authors.forename: Olivia
authors.initials: O
authors.lastname: Dziadek
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000201:enzymology* / Q000473:pathology / Q000517:prevention & control / Q000601:surgery*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D053507:Matrix Metalloproteinase 11 / Q000378:metabolism*; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D053507:Matrix Metalloproteinase 11; D020778:Matrix Metalloproteinase 2